Silence Therapeutics (SLN) Operating Expenses (2024 - 2026)

Silence Therapeutics has disclosed Operating Expenses across 3 years of filings, most recently posting $16.1 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $16.1 million, up 13245.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $77.3 million (up 188.85% YoY), and the FY2025 annual result was $91.4 million, up 584.74% from the prior year.
• Operating Expenses came in at $16.1 million for Q1 2026 at Silence Therapeutics, down from $31.4 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $31.4 million in Q4 2025 to a low of -$3.9 million in Q2 2024.
• The 3-year median for Operating Expenses is $3.4 million (2025), against an average of $11.2 million.
• Across the five-year window, Operating Expenses decreased 5.45% in 2025 and soared 13245.45% in 2026, its largest moves.
• Silence Therapeutics' Operating Expenses stood at $2.6 million in 2024, then jumped by 1090.71% to $31.4 million in 2025, then sank by 48.59% to $16.1 million in 2026.
• The last three Operating Expenses figures came in at $16.1 million (Q1 2026), $31.4 million (Q4 2025), and $26.3 million (Q3 2025), per Business Quant data.